Changes in S100B levels rather than absolute values may be a better marker of severity of septic encephalopathy

Panni, J.K.; Panni, M.K.

doi:10.1093/bja/aen009

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in agreement with the results of other authors (12,15,18). Dr Joana and Moren Panni (19) suggest that S100b changes rather than absolute values may be a better marker of seve ri ty of sepsisassociated encephalopathy. Although S100b originates from the central nervous system (CNS) and increases in cerebrospinal fluid (CSF) after injury (8,20), it remains unclear whether elevation of serum levels of S100b is a sign of blood-brain barrier (BBB) dysfunction, neuronal damage or both.…”

Section: Discussionsupporting

confidence: 93%

S-100β Protein in Patients with Severe Sepsis

Vučeljić¹,

Šurbatović²,

Vujanić³

2009

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Kratak sadr`aj: Uticaj sepse na mozak nije u potpunosti ra z ja{njen. U ovom radu, ispitivali smo vrednosti proteina S100b, kao biomarkera o{te}enja mozga, kod te{ke sepse. Cilj rada bio je da se utvrdi da li su vrednosti proteina S100b povi{ene na samom po~etku bolesti i da li se na osnovu njih mo`e predvideti ishod. Ispitano je 30 pacijenata sa te{kom sepsom, koji su bili podeljeni na pre`ivele (n=8) i umrle (n=22). Za analizu, uzimana je krv u prvih 24h od pojave simptoma. Koncentracija proteina S100b merena je pomo}u imunolo{kog testa meto dom elektrohemiluminiscencije (Elecsys 2010, Roche Dia g no stics). Tako|e, meren je i nivo C-reaktivnog proteina (CRP) imuno ne felometrijskim testom. Od 30 ispitanih pacijenata, 74,4% imalo je povi{ene vrednosti proteina S100b, dok je 25,6% imalo vrednosti u okviru referentnog opsega. Povi{ene vrednosti CRP imalo je svih 30 pacijenata. Izme|u pre `ivelih i umrlih nije bilo statisti~ki zna~ajne razlike u srednjoj vrednosti proteina S100b i CRP (0,390±0,515 vs. 0,415±0,508 mg/L; 98,76±69,94 vs. 161,68±118,38 mg/L). Korelacija izme|u proteina S100b i ishoda nije na|ena. Povi{ene vrednosti S100b ukazuju na verovatna difuzna okultna o{te}enja mozga, koja mogu biti i reverzibilna. Osim toga, protein S100b nije dovoljno pouzdan marker za rano predvi|anje ishoda kod pacijenata obolelih od te{ke sepse.Klju~ne re~i: o{te}enje mozga, C-reaktivni protein, sepsa, S100bSummary: The effects of sepsis on the brain are not fully elucidated. This study investigated the serum levels of S100b protein in severe sepsis, as a biomarker of brain damage. The aim was to determine whether the levels of S100b are increased early, at the onset of sepsis, and if this protein is a good early predictor of outcome. We studied 30 patients with severe sepsis, divided into the survivors (n=8) and norsurvivors (n=22). Blood was sampled within the first 24h after the onset of symptoms. The concentrations of S100b were measu red using an electrochemiluminiscence immu noassay (Elec sys 2010, Roche Diagno stics). Also, we measured the levels of C-reactive protein (CRP) using the immunonephelometric assay. Out of 30 patients, 74.4% had increased levels of S100b, while 25.6% had values within the reference range. A total of 30 patients had increased levels of CRP. The mean values of S100b and CRP did not differ significantly between the survi vors and nonsurvivors (0.390±0.515 vs. 0.415± 0.508 mg/L; 98.76±69.94 vs. 161.68±118.38 mg/L). Corre lation bet ween S100b and outcome was not found. The increased le vels of S100b indicate possible occult diffu se brain injury, that can be reversible. Moreover, the study sho wed S100b protein not to be a good early predictor of outcome in severe sepsis.

show abstract

Section: Discussionsupporting

confidence: 93%

S-100β Protein in Patients with Severe Sepsis

Vučeljić¹,

Šurbatović²,

Vujanić³

2009

Journal of Medical Biochemistry

View full text Add to dashboard Cite

show abstract

“…Finally, in addition to our challenges, other candidate biomarkers which employ correlation to the pathological state of SE are recently addressed: S100β (i.e., astrocyte-secreting protein) [77,[118][119][120], free radicals [121,122], ascorbate [123][124][125], and various neuropeptides [126]. In addition, adult neurogenesis was induced in a rat model of SE and the neurogenesis marker (e.g., 5-bromo-2′-deoxyuridine) might be useful [127].…”

Section: Future Prospectmentioning

confidence: 99%

In Vivo Imaging of Septic Encephalopathy

Imamura¹,

Murakami²,

Matsumoto³

et al. 2017

Sepsis

View full text Add to dashboard Cite

Septic encephalopathy is a devastating symptom of severe sepsis. Many studies have been performed to uncover the pathophysiological mechanisms of septic encephalopathy; however, novel technical approaches are still required to overcome this complex symptom. Because patients are suffering from severe cognitive impairment, coma, or delirium, which burden not only patients but also caregivers, overcoming septic encephalopathy is still a major social problem worldwide, especially in the intensive care. Septic encephalopathy seems to be caused by cytokine invasion and/or oxidative stress into the brain, and this pathological state leads to imbalance of neurotransmitters. In addition to this pathophysiology, septic encephalopathy causes complicated symptoms (e.g., ischemic stroke, edema, and aberrant sensory function). For these pathophysiological mechanisms, electrophysiology using animal models, positron emission tomography (PET), computed tomography, and magnetic resonance imaging for septic patients has provided important clues. However, the research for septic encephalopathy is currently confronted with the difficulty of complex symptoms. To overcome this situation, in this chapter, we introduce our novel methods for in vivo imaging of septic encephalopathy using near infrared (NIR) nanoparticles, quantum dots. In addition to our recent progress, we propose a strategy for the future approach to in vivo imaging of septic encephalopathy.

show abstract

“…Biomarkers such as neuron-specific enolase (NSE) and calcium-binding protein β (S100β) facilitate rapid and cost-effective diagnosis of SAE. [ 11 12 ] However, early measurement of serum S100β levels in SAE patients cannot determine the loss of consciousness. [ 13 ] A study has shown that even elevated levels of serum S100β show no relation to the severity of SAE.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Predictive Levels of Calcium-binding Protein A8 and Tumor Necrosis Factor Receptor-associated Factor 6 in Sepsis-associated Encephalopathy

Zhang

Wang

Long

et al. 2016

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Despite its high prevalence, morbidity, and mortality, sepsis-associated encephalopathy (SAE) is still poorly understood. The aim of this prospective and observational study was to investigate the clinical significance of calcium-binding protein A8 (S100A8) in serum and tumor necrosis factor receptor-associated factor 6 (TRAF6) in peripheral blood mononuclear cells (PBMCs) in diagnosing SAE and predicting its prognosis.Methods:Data of septic patients were collected within 24 h after Intensive Care Unit admission from July 2014 to March 2015. Healthy medical personnel served as the control group. SAE was defined as cerebral dysfunction in the presence of sepsis that fulfilled the exclusion criteria. The biochemical indicators, Glasgow Coma Scale, Acute Physiology and Chronic Health Evaluation score II, TRAF6 in PBMC, serum S100A8, S100β, and neuron-specific enolase were evaluated in SAE patients afresh. TRAF6 and S100A8 were also measured in the control group.Results:Of the 57 enrolled patients, 29 were diagnosed with SAE. The S100A8 and TRAF6 concentrations in SAE patients were both significantly higher than that in no-encephalopathy (NE) patients, and higher in NE than that in controls (3.74 ± 3.13 vs. 1.08 ± 0.75 vs. 0.37 ± 0.14 ng/ml, P < 0.01; 3.18 ± 1.55 vs. 1.02 ± 0.63 vs. 0.47 ± 0.10, P < 0.01). S100A8 levels of 1.93 ng/ml were diagnostic of SAE with 92.90% specificity and 69.00% sensitivity in the receiver operating characteristic (ROC) curve, and the area under the curve was 0.86 (95% confidence interval [CI]: 0.76–0.95). TRAF6-relative levels of 1.44 were diagnostic of SAE with 85.70% specificity and 86.20% sensitivity, and the area under the curve was 0.94 (95% CI: 0.88–0.99). In addition, S100A8 levels of 2.41 ng/ml predicted 28-day mortality of SAE with 90.00% specificity and 73.70% sensitivity in the ROC curve, and the area under the curve was 0.88. TRAF6 relative levels of 2.94 predicted 28-day mortality of SAE with 80.00% specificity and 68.40% sensitivity, and the area under the curve was 0.77. Compared with TRAF6, the specificity of serum S100A8 in diagnosing SAE and predicting mortality was higher, although the sensitivity was low. In contrast, the TRAF6 had higher sensitivity for diagnosis.Conclusions:Peripheral blood levels of S100A8 and TRAF6 in SAE patients were elevated and might be related to the severity of SAE and predict the outcome of SAE. The efficacy and specificity of S100A8 for SAE diagnosis were superior, despite its weak sensitivity. S100A8 might be a better biomarker for diagnosis of SAE and predicting prognosis.

show abstract

Changes in S100B levels rather than absolute values may be a better marker of severity of septic encephalopathy

Cited by 4 publications

References 6 publications

S-100β Protein in Patients with Severe Sepsis

S-100β Protein in Patients with Severe Sepsis

In Vivo Imaging of Septic Encephalopathy

Diagnostic and Predictive Levels of Calcium-binding Protein A8 and Tumor Necrosis Factor Receptor-associated Factor 6 in Sepsis-associated Encephalopathy

Contact Info

Product

Resources

About